Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.9K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.9K
Antigen Processing Pathways01:31

Antigen Processing Pathways

3.2K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
3.2K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.9K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.9K
Multiple Allele Traits01:49

Multiple Allele Traits

39.3K
The Concept of Multiple Allelism
39.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

135
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation of a STRAIGHT-IN Dual AAVS1 hiPSC line with orthogonal landing pads for versatile DNA payload integration.

Stem cell research·2026
Same author

Generation of four human induced pluripotent stem cell lines derived from patients with corticosteroid-associated central serous chorioretinopathy.

Stem cell research·2026
Same author

Picalm coordinates clathrin-mediated endocytosis and actin remodeling during myogenesis.

Molecular metabolism·2026
Same author

Expression and Functional Characterization of Recombinant HLA-DM.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Cut or bind? Antigen-specific processing mechanisms define CD4<sup>+</sup> T cell immunodominant epitopes for SARS-CoV-2 S and N proteins.

Genome medicine·2025
Same author

A systematic review and embryological perspective of pluripotent stem cell-derived autonomic postganglionic neuron differentiation for human disease modeling.

eLife·2025

Related Experiment Video

Updated: Apr 19, 2026

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

16.2K

HLA-DMA polymorphisms differentially affect MHC class II peptide loading.

Miguel Álvaro-Benito1, Marek Wieczorek2, Jana Sticht1

  • 1Institut für Chemie und Biochemie, Freie Universität Berlin, 14195 Berlin, Germany; and.

Journal of Immunology (Baltimore, Md. : 1950)
|December 16, 2014
PubMed
Summary
This summary is machine-generated.

Polymorphisms in HLA-DM, a key immune regulator, can impair its catalytic activity. This reduced function may prolong the presentation of self-peptides, potentially contributing to autoimmune diseases.

More Related Videos

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.8K
Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous &#946;2-Microglobulin
11:17

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Published on: March 10, 2021

6.9K

Related Experiment Videos

Last Updated: Apr 19, 2026

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

16.2K
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.8K
Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous &#946;2-Microglobulin
11:17

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Published on: March 10, 2021

6.9K

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • MHC class II (MHCII) molecules present peptides to CD4(+) T cells during adaptive immunity.
  • HLA-DM facilitates peptide exchange on MHCII, influencing the presented peptide repertoire.
  • While MHCII is polymorphic, HLA-DM shows low variability, but its polymorphisms may impact immune disorders.

Purpose of the Study:

  • To systematically compare the catalytic activity of different HLA-DM variants (DMA*0103/DMB*0101 vs. DMA*0101/DMB*0101).
  • To investigate the impact of specific HLA-DM polymorphisms (G155A and R184H) on peptide exchange and dissociation kinetics.
  • To determine how altered HLA-DM activity affects the presentation of autoantigenic peptides.

Main Methods:

  • Comparative analysis of peptide exchange and dissociation catalyzed by distinct HLA-DM variants.
  • Assessment of direct interactions between HLA-DM variants and HLA-DR/peptide complexes.
  • Measurement of peptide-MHCII complex half-life in the presence of different HLA-DM forms.

Main Results:

  • The DMA*0103/DMB*0101 variant exhibits attenuated catalytic activity compared to DMA*0101/DMB*0101.
  • The G155A substitution in DMA*0103/DMB*0101 significantly reduces peptide release velocity.
  • Peptide-MHCII complexes show a ~2-fold increased half-life with DMA*0103/DMB*0101, prolonging autoantigen persistence.

Conclusions:

  • Specific polymorphic residues in HLA-DM, particularly G155A, considerably impact its catalytic efficiency.
  • Reduced HLA-DM catalytic activity can lead to increased persistence of autoantigenic peptides.
  • HLA-DM polymorphisms represent a potential risk factor for autoimmunity and immune dysregulation.